GLP-1 analogue therapy on glycemic control in patients undergoing cardiac surgery

GLP-1 analogue therapy on glycemic control in patients undergoing cardiac surgery - GLOLIA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008003

Enrollment

Registered

2012-09-01

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes

Interventions

addition to insulin scale therapy, administration of 0.3 mg liraglutide(day -2, -1) and administration of 0.6 mg liraglutide (day 1~10) *day 0 = day of operation Insulin scale therapy from day -2 to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes patient with HbA1c level above 6.0% patients undergoing cardiac surgery patients treated by sulfonyl urea, glinide, DPP4 inhibitor, GLP-1 analogue

Exclusion criteria

Exclusion criteria: patients treated by insulin patients with fasting glucose level above 250 mg/dl patient with pregnancy history of pancreatitis patients with gastorial and/or intestinal disorder

Design outcomes

Primary

Measure	Time frame
Average of M value level of 1,5AG 10 days after operation	—

Secondary

Measure	Time frame
Change in BNP frequency of hypoglycemia frequency of insulin scale change frequency of M value < 10	—

Countries

Japan

Contacts

Public ContactHisashi Makino

National Cerebral and Cardiovascular Center Division of Endocrinology and Metabolism

makinoh@hsp.ncvc.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026